SeqLL Inc. - SQL STOCK NEWS

SeqLL Inc. (NASDAQ: SQL) reported no revenues for Q3 2022, a decline from $50,901 in Q3 2021, due to a temporary halt in operations following its relocation to Billerica, Massachusetts. The gross profit also fell to $0, from $46,852 a year earlier. Research and development costs surged by 373% to $428,771, while general and administrative expenses rose by 36% to $489,729. The net loss widened to $925,949, up 45% from the previous year. The company anticipates resuming normal operations in Q4 2022 as it ramps up R&D efforts.

SeqLL Inc. (NASDAQ: SQL) announced a significant advancement in cancer diagnostics with a new study published in Nature Biotechnology. The research introduces a liquid biopsy approach called EPINUC, utilizing SeqLL’s tSMS® platform for early cancer detection, specifically colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC). The study achieved a 0.96 AUC, with 92% sensitivity at 85% specificity for CRC samples. The implications of this work may extend beyond cancer, potentially aiding in diagnosing other diseases that impact blood biomarkers.

SeqLL Inc. (NASDAQ: SQL) announced a significant advancement in cancer diagnostics through a new study published in Nature Biotechnology. Utilizing its tSMS® platform, the study demonstrated high potential for early cancer detection, achieving a 0.96 AUC, 92% sensitivity, and 85% specificity for colorectal cancer (CRC) diagnostics. This innovative liquid biopsy approach, named EPINUC, analyzed protein biomarkers and epigenetic modifications from a minimal plasma sample. With CRC being the third most common cancer globally, this breakthrough highlights the importance of SeqLL’s technology in improving early disease detection and treatment.

BILLERICA, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- SeqLL, a technology company specializing in life sciences, announced that CEO Daniel Jones will present a corporate overview at the H.C. Wainwright 24th Annual Global Conference from September 12-14, 2022. The presentation will be available on-demand starting at 7:00 am ET on September 12. Attendees can register to view the presentation and request 1x1 meetings. SeqLL aims to advance genomic medicine through its True Single Molecule Sequencing platform, developing innovative solutions for scientific research.

SeqLL Inc. (NASDAQ: SQL, SQLLW) received a notice from Nasdaq about non-compliance with Listing Rule 5550(a)(2) due to a closing bid price below $1.00 for 30 consecutive business days. They have until December 18, 2022, to regain compliance by achieving a bid price of at least $1.00 for 10 consecutive days. If unsuccessful, they could be granted a second compliance period but must still meet other listing requirements. Despite this challenge, the CEO expresses confidence in the company's future and technology advancements.

SeqLL Inc. (NASDAQ: SQL; SQLLW) announced a study published in Cell Reports, utilizing its single-molecule epigenetic profiling technology. The research, focusing on pediatric brain cancer mutations, provides insights into glioma epigenetics through single-nucleosome imaging. Lead authors from Weizmann Institute revealed mechanisms of tumorigenesis, potentially impacting genomics research significantly. CEO Daniel Jones expressed excitement over the technology's application in understanding cancer, which could lead to breakthroughs in treatment.

SeqLL Inc. (NASDAQ: SQL; SQLLW) reported its Q1 2022 financial results, showing a 22% decline in revenue to $47,482, attributed to reduced activity during its relocation to Billerica, Massachusetts. Gross profit increased 45% to $47,482, as the company had no product sales or research services. R&D expenses surged 1,764% to $334,670, reflecting a return to pre-pandemic levels. General and administrative expenses rose by 51% to $584,872. The net loss decreased 34% to $937,954, aided by no losses on debt extinguishment in 2022. Cash reserves stood at $8.9 million.

SeqLL Inc. (NASDAQ: SQL; SQLLW) reported its financial results for 2021, highlighting a 36% decline in total revenues to $0.21 million due to reduced business activities amid the COVID-19 pandemic. Gross profit margin improved to 72%, but net loss increased to $3.7 million or ($0.51) per share. R&D expenses rose 60% to $0.53 million reflecting a return to pre-pandemic levels. The company had $9.9 million in cash and equivalents as of December 31, 2021, and established a Scientific Advisory Board to explore new development opportunities.

BILLERICA, Mass., March 24, 2022 – SeqLL Inc. (NASDAQ: SQL; SQLLW) announced its CEO, Daniel Jones, will participate in the 2022 Virtual Growth Conference from March 28-30, 2022. The presentation will be available on demand starting at 9:00 am ET on March 28. Interested attendees can register for the event, and the archived webcast will be accessible on the Company’s investor relations website. SeqLL specializes in life sciences instrumentation and research services, focusing on advancing genomic medicine through its True Single Molecule Sequencing platform.